Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Interest & Investment Income (2016 - 2023)

Rein Therapeutics (RNTX) has disclosed Interest & Investment Income for 8 consecutive years, with $155000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Interest & Investment Income rose 40.91% to $155000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $432000.0, a 114.93% increase, with the full-year FY2019 number at $587000.0, up 65.35% from a year prior.
  • Interest & Investment Income was $155000.0 for Q3 2023 at Rein Therapeutics, up from $112000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $208000.0 in Q2 2019 to a low of $5000.0 in Q3 2020.
  • A 5-year average of $76312.5 and a median of $58500.0 in 2020 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: crashed 96.99% in 2020, then skyrocketed 423.81% in 2022.
  • Rein Therapeutics' Interest & Investment Income stood at $114000.0 in 2019, then crashed by 95.61% to $5000.0 in 2020, then soared by 320.0% to $21000.0 in 2021, then surged by 423.81% to $110000.0 in 2022, then soared by 40.91% to $155000.0 in 2023.
  • Per Business Quant, the three most recent readings for RNTX's Interest & Investment Income are $155000.0 (Q3 2023), $112000.0 (Q2 2023), and $55000.0 (Q1 2023).